ABSTRACT
In this paper, we present different strategies to vectorize HldE kinase inhibitors with the goal to improve their gram-negative intracellular concentration. Syntheses and biological effects of siderophoric, aminoglycosidic, amphoteric, and polycationic vectors are discussed. While siderophoric and amphoteric vectorization efforts proved to be disappointing in this series, aminoglycosidic and polycationic vectors were able for the first time to achieve synergistic effects of our inhibitors with erythromycin. Although these effects proved to be nonspecific, this study provides information about the required stereoelectronic arrangement of the polycationic amines and their basicity requirements to fulfill outer membrane destabilization resulting in better erythromycin synergies.
Subject(s)
Erythromycin/metabolism , Escherichia coli/metabolism , Multienzyme Complexes/antagonists & inhibitors , Nucleotidyltransferases/antagonists & inhibitors , Phosphotransferases (Alcohol Group Acceptor)/antagonists & inhibitors , Aminoglycosides/pharmacology , Anti-Bacterial Agents/metabolism , Erythromycin/chemistry , Erythromycin/pharmacology , Escherichia coli/drug effects , Lipopolysaccharides/biosynthesis , Microbial Sensitivity Tests , Multienzyme Complexes/drug effects , Nucleotidyltransferases/drug effects , Phosphotransferases (Alcohol Group Acceptor)/drug effects , Polyamines/pharmacology , PolyelectrolytesABSTRACT
We report here the optimization of an HldE kinase inhibitor to low nanomolar potency, which resulted in the identification of the first reported compounds active on selected E. coli strains. One of the most interesting candidates, compound 86, was shown to inhibit specifically bacterial LPS heptosylation on efflux pump deleted E. coli strains. This compound did not interfere with E. coli bacterial growth (MIC > 32 µg/mL) but sensitized this pathogen to hydrophobic antibiotics like macrolides normally inactive on Gram-negative bacteria. In addition, 86 could sensitize E. coli to serum complement killing. These results demonstrate that HldE kinase is a suitable target for drug discovery. They also pave the way toward novel possibilities of treating or preventing bloodstream infections caused by pathogenic Gram negative bacteria by inhibiting specific virulence factors.
Subject(s)
Anti-Bacterial Agents/chemical synthesis , Benzothiazoles/chemical synthesis , Escherichia coli/drug effects , Multienzyme Complexes/antagonists & inhibitors , Nucleotidyltransferases/antagonists & inhibitors , Phosphotransferases (Alcohol Group Acceptor)/antagonists & inhibitors , Triazines/chemical synthesis , Anti-Bacterial Agents/chemistry , Anti-Bacterial Agents/pharmacology , Benzothiazoles/chemistry , Benzothiazoles/pharmacology , Escherichia coli/pathogenicity , Lipopolysaccharides/pharmacology , Microbial Sensitivity Tests , Structure-Activity Relationship , Triazines/chemistry , Triazines/pharmacology , Virulence/drug effectsABSTRACT
In this paper, we present some elements of our optimization program to decouple triclosan's specific FabI effect from its nonspecific cytotoxic component. The implementation of this strategy delivered highly specific, potent, and nonbiocidal new FabI inhibitors. We also disclose some preclinical data of one of their representatives, 83, a novel antibacterial compound active against resistant staphylococci and some clinically relevant Gram negative bacteria that is currently undergoing clinical trials.
